金斯瑞生物科技(01548.HK)：高瓴擬認購Probio Cayman A類優先股及認股權證
格隆匯8月19日丨金斯瑞生物科技(01548.HK)發佈公吿，有關涉及公司與高瓴資本就公司間接全資附屬公司Probio Cayman建議A輪融資。2021年8月18日(紐約時間)(2021年8月19日交易時段前，北京時間)，Probio Cayman與高瓴投資管理有限公司訂立購買協議，據此，Probio Cayman同意出售及發行而投資者同意購買總計3億股A類優先股，總代價約1.5億美元(相當於約11.68億港元)；及Probio認股權證，以在完成時以約1.25億美元(相當於約9.736億港元)的總代價購買總計189,393,939股Probio股份。
投資者MSUM VII Holdings Limited與HSUM XIV Holdings Limited均為根據開曼羣島法律成立的公司。高瓴投資管理有限公司是他們唯一的管理公司。於該公吿日期，Probio Cayman由公司透過其全資附屬公司Probio BVI間接全資擁有。完成後，Probio BVI於Probio Cayman的股權將攤薄至82.95%(不考慮未來配售和發行ESOP股份，且假設Probio認股權證已全面行使，及可轉換股債券尚未轉換為Probio股份)。
Probio Cayman為公司的間接全資附屬公司，於2021年5月7日在開曼羣島註冊成立為獲豁免有限公司。Probio集團提供抗體藥物發現、臨牀前抗體藥物開發、抗體藥物臨牀開發、臨牀前及臨牀階段的質粒及病毒開發等四大類綜合服務。該等服務及相關產品助力生物製藥及生物技術公司從藥物發現階段到臨牀前乃至臨牀開發階段，加速在綜合平台開發治療性抗體，以及基因或細胞治療產品的質粒及病毒載體。
購買事項的所得款項擬用於滿足Probio Cayman主營業務經營中的資本開支及其他一般營運資金需要。公司相信，購買事項將提供額外的資金來源，以用作Probio Cayman建立良好生產規範(GMP)製造能力及研發實力，以發展現有業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
